Efficacy of famciclovir in the treatment of lamivudine resistance related to an atypical hepatitis B virus mutant

Transplantation

Volumn 73, Issue 1, 2002, Pages 148-151

  Tang, Sydney ^a   Ho, Stephen K N ^a   Moniri, Kelly ^b   Lai, Kar Neng ^a   Chan, Tak Mao ^a,c  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b GLAXOSMITHKLINE   (United Kingdom)

^c QUEEN MARY HOSPITAL   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; FAMCICLOVIR; ISOLEUCINE; LAMIVUDINE; LEUCINE; METHIONINE; OLIGONUCLEOTIDE; PREDNISOLONE; TYROSYLMETHIONYLASPARTYLASPARTIC ACID; UNCLASSIFIED DRUG; VALINE;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DIAGNOSTIC PROCEDURE; DISEASE COURSE; DRUG EFFICACY; FEMALE; GENETIC ANALYSIS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; VIRAL GENETICS; VIRUS MUTANT; VIRUS REACTIVATION; VIRUS RESISTANCE;

EID: 0037080758     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200201150-00028     Document Type: Article

References (34)

1. Variability in the morphological spectrum and clinical outcome of chronic liver disease in hepatitis B-positive and B-negative renal transplant recipients
2. The impact of renal transplantation on the course of hepatitis B liver disease
3. Hepatitis C in renal transplant recipients
4. A preliminary trial of lamivudine for chronic hepatitis B infection
5. A one-year trial of lamivudine for chronic hepatitis B
6. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy
7. Two sensitive PCR-based methods for detection of hepatitis B virus variants associated with reduced susceptibility to lamivudine
8. Selection of multiresistant hepatitis B virus during sequential nucleoside-analogue therapy
9. Experience with lamivudine against hepatitis B virus
10. Comparison of the second-generation digene hybrid capture assay with the branched-DNA assay for measurement of hepatitis B virus DNA in serum
11. Treatment of fibrosing cholestatic hepatitis with lamivudine
12. Efficacy and safety of lamivudine on replication of recurrent hepatitis B after cadaveric renal transplantation
13. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine
14. Mutations in the hepatitis B DNA polymerase associated with antiviral resistance
15. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation
16. Generation of duck hepatitis B virus polymerase mutants through site-directed mutagenesis which demonstrate resistance to lamivudine [(-)-beta-L-2′, 3′-dideoxy-3′-thiacytidine] in vitro
17. Effects of extended lamivudine therapy in asian patients with chronic hepatitis B
18. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation
19. Lamivudine therapy in patients undergoing liver transplantation for hepatitis B virus precore mutant-associated infection: High resistance rates in treatment of recurrence but universal prevention if used as prophylaxis with very low dose hepatitis B immune globulin
20. Late breakthrough of HBV viremia with lamivudine as a single agent for prevention of graft reinfection in liver transplantation for cirrhosis secondary to hepatitis B
21. Consensus symposium on combined antiviral therapy
22. Advances in the treatment of chronic hepatitis B virus infection
23. Clinical experience with famciclovir against hepatitis B virus
24. Inhibition of hepatitis B virus DNA polymerase by enantiomers of penciclovir triphosphate and metabolic basis for selective inhibition of HBV replication by penciclovir
25. Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir in vitro
26. Enhancement of natural killer activity and interferon induction by different acyclic nucleoside phosphonates
27. A placebo-controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection
28. Adefovir dipivoxil
29. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro
30. Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors
31. Fulminant hepatic failure resulting from lamivudine-resistant hepatitis B virus in a renal transplant recipient: Durable response after orthotopic liver transplantation on adefovir dipivoxil and hepatitis B immune globulin
32. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants
33. Clinical potential of emerging new agents in hepatitis B
34. Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir